T
here are an estimated 250 000 to 400 000 sudden cardiac deaths (SCD) annually in the United States, 1 and more than half are the initial manifestation of heart disease. 2 Although the majority of these deaths are associated with coronary artery disease, 3 the factors determining predisposition to arrhythmia in the presence of ischemia or infarction remain poorly understood. There is emerging evidence that a proportion of the familial contribution to SCD risk is distinct from that associated with other manifestations of atherosclerosis. 4 -6 For example, individuals with a familial history of SCD are more likely to have SCD 6 or ventricular fibrillation during acute myocardial infarction. 5 These data suggest that there may be genetic factors that confer a predisposition to fatal ventricular arrhythmias even in the setting of atherosclerosis or other acquired disease states.
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Cardiac ion channels play a critical role in cardiac electrophysiology, 7 and perturbation of their function can result in SCD by lethal ventricular arrhythmias in a wide range of conditions. 8 Although many ion channels and other proteins are involved in the genesis and maintenance of normal cardiac rhythm, genetic analyses of rare arrhythmic disorders have definitively established a critical role for 5 particular ion channel genes in arrhythmia vulnerability. 8, 9 These genes encode the cardiac sodium channel (SCN5A), and ion channels regulating the slow component (KCNQ1 and KCNE1) and the rapid component (KCNH2 and KCNE2) of the delayed rectifier potassium current (I Ks and I Kr , respectively). Although the primary arrhythmic disorders associated with mutations in these same genes are rare, there are data to suggest that common variants may result in subclinical alterations in ion channel function 10 -17 that may only become clinically manifest in the setting of other proarrhythmic factors, such as atherosclerosis or drug exposure.
To address the hypothesis that common variants in these genes might be associated with SCD within the general population, we assembled SCD cases from 6 National Institutes of Health (NIH)-funded prospective cohorts and used a prospective nested case-control design to test for associations between common genetic variation in coding and noncoding regions of these 5 ion channel genes and SCD among individuals of European ancestry.
Methods

Study Populations
The prospective cohorts included in the present investigation include the Physicians' Health Study (PHS I and II), the Nurses' Health Study (NHS), the Health Professionals Follow-up Study (HPFS), the Women's Health Study (WHS), and the Women's Antioxidant Cardiovascular Study (WACS). Together, these cohorts include a total of 40 878 men and 67 093 women with stored blood samples. The details of the cohorts along with the proportion of participants who donated blood samples at baseline are outlined in Supplemental  Table 1 . In brief, the NHS and HPFS are prospective observational cohort investigations, and the PHS I, WHS, and WACS studies were initially randomized trials of aspirin and/or vitamin supplements in which the intervention phases have ended. Prospective follow-up is ongoing in PHS I and WHS. The PHS II is an ongoing randomized trial of vitamin supplementation. Information about medical history, lifestyle factors, and incident disease is assessed either annually or biennially by self-administered questionnaires.
End Point Confirmation
The study end points include incident cases of sudden and/or arrhythmic cardiac death that occurred after return of the blood sample and before April 1, 2007. All cohorts used similar methods to document end points, as has been previously described in detail. 18 Among the individuals who donated blood samples at baseline, 540 sudden/arrhythmic deaths were confirmed, and 536 of these had DNA samples that passed our quality control standards. A cardiac death was considered a definite SCD if the death or cardiac arrest that precipitated death occurred within 1 hour of symptom onset as documented by medical records or next-of-kin reports (nϭ389, 72.6%) or had an autopsy consistent with SCD (ie, acute coronary thrombosis or severe coronary artery disease without myocardial necrosis or other pathological findings to explain death; nϭ23, 4.3%). Unwitnessed deaths or deaths that occurred during sleep were considered probable SCDs if the participant was documented to be symptom-free when last observed within the preceding 24 hours and circumstances suggested that the death could have been sudden (nϭ92, 17.2%). 19 Deaths were also classified as arrhythmic or nonarrhythmic based on the definition of Hinkle and Thaler. 20 An arrhythmic death was defined as an abrupt spontaneous collapse of the circulation (pulse disappeared) without evidence of prior circulatory impairment (shock, congestive heart failure) or neurological dysfunction (change in mental status, loss of consciousness, or seizure). Deaths before which the pulse gradually disappeared and/or those preceded by circulatory or neurological impairment were considered nonarrhythmic deaths, and these deaths were excluded from the SCD end point even if the death occurred within 1 hour of symptom onset. Deaths that fulfilled the criteria for arrhythmic death but were preceded by greater than 1 hour of symptoms (nϭ32, 6.0%) were also included in the combined end point of sudden and/or arrhythmic cardiac death.
Selection of Control Subjects
Using risk-set sampling, 21 we randomly selected up to 3 control subjects for each case matched on study cohort, sex, age (Ϯ1 year), ethnicity, smoking status (current, never, past), time and date of blood sampling, fasting status, and presence or absence of cardiovascular disease (myocardial infarction, angina, coronary artery bypass grafting, or stroke) before death. Since very few cases among other ethnicities (nϭ20) occurred in these predominantly Europeanderived cohorts and to reduce the risk of population stratification, analyses were limited to self-described whites (nϭ516).
Linkage Disequilibrium Characterization and Single Nucleotide Polymorphism Selection
Given recent data highlighting the importance of noncoding regions in genetic association studies 22 and on ion channel function, 14 we tested for associations between single nucleotide polymorphisms (SNPs) in both coding and noncoding regions of the candidate genes, including 5 kb upstream and downstream using a tag SNP strategy. We used genotypes available from the International HapMap CEU (release 22) sample of northern and western European ancestry (120 independent chromosomes), and the program Tagger 23 was used to select tag SNPs that capture SNPs with minor allele frequency Ն5% in the reference pedigrees at a minimum r 2 of 0.8. A total of 137 tag SNPs were selected and successfully genotyped. We also genotyped 5 additional noncoding variants shown to be associated with QT interval duration in a recent genome-wide association study 16 
Fine Mapping of Associated SNPs
For tag SNPs found to be associated with sudden/arrhythmic death, we attempted to further refine the signals of association by additionally genotyping partially correlated SNPs. Specifically, we examined all SNPs within 50 kb of the associated variant (sentinel SNP) in HapMap CEU (release 24) and identified variants (target SNPs) with r 2 Ͼ0.20 to the sentinel SNP. We then selected a parsimonious subset of fine-mapping SNPs using Tagger such that every target SNP was captured by pairwise correlation r 2 Ͼ0.80 to any one of the finemapping SNPs.
Genotyping and Quality Control
Genomic DNA was extracted from the buffy coat fraction of centrifuged blood using Qiagen Autopure kits (Valencia, Calif) in NHS, HPFS, and WACS and from whole blood in PHS I. In WHS and PHS I, DNA was extracted using the MagNA Pure LC instrument with the MagNA Pure LC DNA isolation kit (Roche Applied Science, Penzberg, Germany). All assays were conducted without knowledge of case status, and samples were labeled by study code only. Matched case-control pairs were handled identically and assayed in the same analytic run. All cohort DNA samples were genotyped together in the same experiment. For all SNPs except rs1805123 in KCNH2, genotyping was performed on the Sequenom platform (San Diego, Calif), which resolves allele-specific singlebase extension products using mass spectrometry (MALDI-TOF). DNA samples with successful genotyping on fewer than 60% of SNPs selected were excluded from analysis. Genotypes for SNPs included in the analysis passed our quality control thresholds (call rate Ն95%, Hardy-Weinberg equilibrium PϾ0.01 in control subjects). Blinded replicate quality control samples were included and genotyped with 99.82% agreement. Genotyping for rs1805123 was performed using a TaqMan 5-nuclease allelic discrimination assay with standard protocols, and blinded replicate quality control samples were genotyped with 100% agreement.
Statistical Analysis
Means or proportions for baseline cardiac risk factors were calculated for cases and control subjects. The significance of risk factor associations were tested with the 2 statistic for categorical variables and with the Student t test for continuous variables. For each cohort, we investigated deviation from Hardy-Weinberg equilibrium among control subjects using a 2 goodness-of-fit test. We analyzed the association between each SNP and the risk of sudden and/or arrhythmic cardiac death using conditional logistic regression analysis. With risk-set analysis, the odds ratio derived from the logistic regression directly estimates the hazard ratio and thus the rate ratio or relative risk. 21 In the primary meta-analysis, the conditional odds ratios for each of the individual tag SNPs were estimated for each cohort separately under an additive model of inheritance. For the nonsynonymous SNPs, we assessed genetic effects under all 3 modes of inheritance: additive, dominant, and recessive, because prior studies reported testing of different genetic models for the nonsynonymous SNPs. Fixed-effect meta-analyses using inverse variance weights were conducted based on the summary conditional logistic regression results for each cohort, 26 and PROC MIXED in SAS was used for estimation of the summary effects. Tests for heterogeneity of the genetic effect across sites were conducted using the Q-statistic. 27 To adjust for multiple comparisons, the false discovery rate (FDR) 28 was computed for each SNP based on the number of SNPs tested for each candidate gene, and an FDR Ͻ0.05 was used as the threshold for statistical significance for tag SNPs without a prespecified hypothesis.
We then further adjusted these conditional logistic regression models for additional factors. Of the matching variables, age and smoking were not perfectly matched, and therefore these variables were also entered into the conditional logistic regression models to avoid any potential for residual confounding. The first multivariable model adjusted for age, and the second multivariable model further adjusted for standard cardiac risk factors including body mass index; history of diabetes, hypertension, hyperlipidemia, and smoking. The third additionally adjusted for family history of myocardial infarction, alcohol intake, physical activity, and aspirin use (randomized aspirin treatment in WHS, PHS I, and reported aspirin use in the other studies). The randomized vitamin therapies in the trials had no effect on any cardiovascular outcome and therefore we do not adjust for their use in the model.
Statistical analysis was performed using SAS statistical software (SAS Institute Inc, Cary, NC), Version 9.1.
Results
A total of 516 cases (188 women and 328 men) of sudden and/or arrhythmic cardiac deaths occurred among subjects with European ancestry in the 6 cohorts over an average follow-up of 13.0 years. The clinical characteristics of the 516 cases and 1522 control subjects are displayed by study cohort in Table 1 . The mean age of the cases was 64.2 years, and 201 (39.0%) reported a history of cardiovascular disease before the SCD. In pooled analyses, cases were more likely to report a history of diabetes, hypertension, and a higher body mass index (PϽ0.005 for all comparisons). Cases did not differ significantly with respect to a history of hypercholesterolemia, family history of myocardial infarction, and/or aspirin use from the control subjects. Of the total study group, 509 cases and 1507 matched control subjects were successfully genotyped according to our prespecified criteria. The genotyping call rates for the 142 SNPs ranged from 96.1% to 100%. There was no difference in the average call rate between cases and control subjects (97.2% versus 97.1%).
Association Between Ion Channel Tag SNPs and SCD
The full results from the primary fixed-effects meta-analysis for each of the 137 ion channel tag SNPs and the 5 intronic SNPs known to be associated with QT interval are outlined in the supplement (supplementary Table 2 ). Fifteen of the 142 SNPs were nominally significant (PϽ0.05) under an additive genetic model of inheritance in 3 of the genes. These included 4 of 9 tested in KCNE1, 7 of 68 in KCNQ1, and 4 of 47 in SCN5A. None of the intronic SNPs known to be associated with QT interval or the tag SNPs in KCNE2 and KCNH2 reached this level of significance. To account for multiple tests within each gene, we computed the FDR, and 2 tag SNPs (rs2283222 in KCNQ1) and (rs11720524 in SCN5A) remained significantly associated with sudden/arrhythmic death (FDRϭ0.01 and 0.03, respectively). SNP rs2283222 is located in intron 11 in KCNQ1 ( Figure 1 ) and rs11720524 is located in intron 1 of SCN5A near the promoter region ( Figure 2 ). Another SNP in KCNE1, rs11701049, was of borderline significance (FDRϭ0.051).
In an attempt to further refine the signals of association at KCNQ1 and SCN5A, we genotyped an additional 10 SNPs with r 2 Ͼ0.20 to rs2283222 (KCNQ1) or rs11720524 (SCN5A), respectively, and 1 SNP at each locus failed. None of the 8 passing fine-mapping SNPs were more strongly associated with sudden/arrhythmic death than the 2 sentinel SNPs (Supplementary Table 3) . Table 2 displays the individual cohort-specific associations for the "at risk" allele for the 2 sentinel SNPs that remained associated with sudden/arrhythmic death after accounting for multiple testing. Allele frequencies did not differ among the control groups (Pϭ0.33 for rs2283222 and Pϭ0.84 for rs11720524). The pooled at-risk or major allele frequency was 0.67 for the T-allele in rs2283222 and 0.60 for the C-allele in rs11720524. The associations of both SNPs with sudden/arrhythmic death were largely consistent across the 6 studies (Table 2) , and the test for heterogeneity of the odds ratios was nonsignificant (Pϭ0.65 for rs2283222 and Pϭ0.58 for rs11720524).
Further control for age and other cardiovascular and lifestyle risk factors (Table 3) did not materially affect these associations. In the full multivariable model, the odds ratio (OR) for sudden/arrhythmic death was 1.39 per T-allele copy (95% confidence interval [CI], 1.16 to 1.66; Pϭ0.0003) for rs2283222 and 1.34 (95% CI, 1.13 to 1.58; Pϭ0.0007) per C-allele copy for rs11720524. Results for both SNPs were also not materially altered in sensitivity analyses excluding possible SCDs (Table 3) . To demonstrate the independent associations for each SNP, we included both SNPs in the fully adjusted multivariable model and found that both SNPs remained strongly associated with sudden/arrhythmic death (ORϭ1.38/T-allele copy; 95% CI, 1.16 to 1.64; Pϭ0.0002 for rs2283222 and ORϭ1.36/C-allele copy; 95% CI, 1.16 to 1.60; Pϭ0.0002 for rs11720524).
Association Between Nonsynonymous SNPs and SCD
In addition to the linkage disequilibrium-based approach relating common genetic variation in the 5 candidate genes, we directly tested 5 nonsynonymous SNPs. Table 4 lists the results obtained in the primary fixed-effects meta-analysis for these SNPs under dominant, additive and recessive genetic modes of inheritance. None of these SNPs achieved a Shown are the individual cohort-specific and combined meta-analysis ORs (95% CI) for increasing copy of the "at risk" T-allele of rs2283222 in KCNQ1 and C-allele of rs11720524 in SCN5A from the conditional logistic regression models under an additive model of inheritance. Shown are the meta-analysis ORs (95% CI) with increasing levels of risk factor adjustment for increasing copy of the T-allele of rs2283222 in KCNQ1 and the C-allele of rs11720524 in SCN5A.
*Sensitivity analysis: Excluding probable sudden cardiac death cases (ie, unwitnessed deaths or deaths that occurred during sleep where the participant was documented to be symptom-free when last observed within the preceding 24 hours). †Multivariable model 1: Controlled simultaneously for age, smoking status (current, past, never), body mass index (continuous), history of diabetes, hypertension, and high cholesterol. ‡Multivariable model 2: Controlled for variables listed above in multivariable model 2 and family history of myocardial infarction, alcohol intake (Ͻweekly, weekly, daily, Ն2 per day), physical activity (at least once per week), and aspirin (Ն11 days per month).
nominal level of significance in any of the genetic models or after multivariable adjustment (data not shown).
Discussion
In this combined, nested, case-control analysis from 6 prospective cohorts, 2 common intronic variants in KCNQ1 and SCN5A were significantly associated with sudden and/or arrhythmic death in individuals of European ancestry after adjustment for multiple testing. The at-risk alleles are common, with population frequencies of 67% for the T-allele at rs2283222 in KCNQ1 and 60% for the C-allele at rs11720524 in SCN5A. The associations between each allele and sudden and/or arrhythmic death were independent of the other and were not mediated by established coronary heart disease risk factors. In the full multivariable models including both variants, each of the at risk alleles was associated with a 39% to 41% higher odds ratio of sudden/arrhythmic death. None of the 5 nonsynonymous SNPs tested were associated with sudden/arrhythmic death in the combined sample.
Rare mutations in these 2 ion channel genes have been associated with rare mendelian arrhythmic disorders, most notably the long-QT syndrome. KCNQ1 encodes the ␣-subunit of the slow component of the delayed rectifier potassium current, and mutations in this gene account for the majority of long-QT syndrome cases. 7, 9 Mutations in SCN5A, which encodes the cardiac sodium channel, are a less common cause of long-QT syndrome but are also associated with multiple other discrete phenotypes with a propensity for ventricular arrhythmias, most notably the Brugada syndrome. 8, 9 Recently, mutations and rare variants with functional effects in SCN5A and KCNQ1 were found in 6.5% of sudden infant death syndrome victims, 29 and rare variants in SCN5A were found in 10% of a sample of SCD cases among women within one of these populations. 30 To our knowledge, this is the first study linking common variation in these ion channel genes to sudden arrhythmic death within the general population. Common variants in introns and exons of these genes have previously been documented to modify ion channel function in cellular electrophysiology studies 10, 14 and to be associated with conduction intervals 13 and repolarization phenotypes measured 16,17 on the ECG. As has been previously documented for intermediate traits such as QT interval 31 and other complex phenotypes, 22 common variation in intronic DNA sequence exhibited stronger associations with sudden/arrhythmic death than known common exonic missense SNPs. Presumably these intronic variants exert their influence through gene expression, and although neither SNP is in strong LD with a known coding variant, further work will be required to exclude coding variants as the source of these association signals. Future studies on the genetic basis of arrhythmic risk will need to include functional analyses of noncoding variants as well as those that result in amino acid changes.
Although, we found that sequence variants at the KCNQ1 and SCN5A loci are associated with sudden/arrhythmic death risk, it is not known whether these specific SNPs are the functional variants or are in LD with a functional allele. Our fine mapping did not find a more strongly associated correlated allele; however, deep resequencing would be required to fully define the set of all candidate alleles, and much larger sample sizes would be required to distinguish among all correlated alleles at the locus. The SNPs are also not in LD with other common intronic variants in these same genes recently found to be associated with QT interval, 16, 17 and 5 noncoding variants in KCNQ, KCNH2 and SCN5A that influence QT interval 16 were not associated with sudden/ arrhythmic death in these cohorts.
From a pathophysiological standpoint, these data suggest that common variation in genes that directly influence cardiac electrophysiology may influence SCD risk at the population level. Recently, variation at a genetic locus found to influence QT interval, the nitric oxide synthase 1 adaptor protein (NOS1AP) gene, was also found to be associated with SCD in 2 population-based studies. 32 These genetic markers, once validated in other populations, may eventually be useful for SCD risk prediction in combination with markers for other pathways contributing to SCD risk such as atherosclerosis 33 and/or autonomic instability. Regardless of such populationlevel application, further study of the functional consequences of these variants on cardiac electrophysiology may lead to important advances in our understanding of the mechanisms underlying SCD and could ultimately lead to novel therapeutic approaches.
Strengths of the present analysis include the large, wellcharacterized cohorts, the combined large number of rigorously confirmed sudden and/or arrhythmic cardiac deaths, and the prospective design that allowed us to match on follow-up time at risk reducing survival bias. The study also has several limitations that deserve consideration. First, the low frequency at which SCD occurs in the general population and the inherent difficulties in documenting the circumstances surrounding out of hospital deaths in free living populations limits the number of rigorously phenotyped SCD cases even in large cohort studies. As a result, we needed to pool cases from independent cohorts to achieve adequate statistical power. Although the associations between both of the SNPs and sudden/arrhythmic death were relatively consistent across the 6 studies, this does not substitute for an independent replication study of comparable size and phenotype, which would be needed to establish certainty regarding the observed associations. Second, although coronary heart disease underlies the majority of SCDs, 3 other pathologies account for a sizeable minority, especially among women. 34 Therefore, associations may differ depending on presence and type of underlying structural heart disease. The absence of autopsy data in this population-based study precludes our examination of this important question. Also, we did not have power to evaluate with certainty other plausible interactions by age, sex, and cardiovascular disease status as well as gene-gene interactions. Similarly, there were variants of borderline significance that may have reached statistical significance in a larger sample size. Third, our study sample is of European ancestry, and the relevance of the 2 variants described to populations of different ancestry is unknown. Fourth, baseline ECGs were not collected in these cohorts, and therefore we did not have data on potential electrocardiographic intermediate markers, such as QRS duration and QT interval. Finally, the selective composition of the cohorts, US health professionals, may limit the generalizability of the findings to other populations with differing prevalence of cardiovascular disease and/or cardiovascular disease risk factors.
In summary, common variants in the genes encoding the slow component of the cardiac potassium channel (KCNQ1) and the ␣-subunit of the cardiac sodium channel (SCN5A) are associated with significantly increased risks of sudden and/or arrhythmic cardiac death in this combined population of European-derived men and women. These findings highlight the important role these 2 cardiac ion channel channels may play in propensity toward fatal ventricular arrhythmias not only in the rare primary arrhythmic disorders but also in more common forms of sudden cardiac death. Therefore, further investigation into the functional abnormalities associated with noncoding variation in these genes may lead to important insights regarding mechanisms underlying ventricular arrhythmias in the general population. Ultimately, if these findings are replicated in other populations, variants in these genes in combination with other validated genetic, biological, and environmental SCD risk markers may advance risk prediction for this lethal and poorly predicted outcome.
